REGN stock is trading at $748.87 — we rate it a Hold with a $805 average price target, even after a 22.6% YTD decline. The drop reflects real Eylea biosimilar pressure, but Regeneron’s drug pipeline, Dupixent expansion, and Eylea HD label extension argue the selloff is overdone. If you’re researching REGN stock price, the question right now isn’t whether the business is broken — it’s whether the multiple has overcorrected.
So why is REGN stock dropping in 2026, and is the dip worth buying? Below is the full REGN stock price analysis — Key Stock Data, valuation, named analyst targets, the bull-vs-bear case, and what to do next.
| Metric | Value |
|---|---|
| Current Price | $748.87 |
| 52-Week Range | $546.30 – $1,211.20 |
| Market Cap | $80.1B |
| P/E Ratio (Forward) | 17.3x |
| EPS (TTM) | $36.18 |
| Analyst Consensus | Moderate Buy |
| Average Price Target | $805.00 |
| YTD Performance | -22.6% |
Table of Contents
- Key Takeaways on REGN Stock
- What Is Regeneron Pharmaceuticals (REGN)?
- Why Is REGN Stock Dropping in 2026?
- REGN Stock Price Recent Performance
- REGN Valuation Analysis: Is the Multiple Too Cheap?
- Bullish and Bearish Analyst Opinions on REGN
- REGN Analyst Price Targets and Consensus Rating
- How to Trade REGN via MEXC
- REGN Stock FAQ
Key Takeaways on REGN Stock
- Price & verdict: REGN trades at $748.87 with a $805 average target — Hold rating with upside skewed to a recovery scenario.
- Why REGN stock is dropping: Eylea (aflibercept) biosimilar competition from Amgen’s Pavblu and Samsung Bioepis’s Opuviz is compressing the franchise that historically supplied ~40% of revenue.
- Bull case stat: Eylea HD (the 8mg high-dose formulation) won an extended dosing label in 2026, with management guiding for it to offset biosimilar erosion by 2027.
- Bear case stat: Eylea base-version revenue fell roughly 25% year-over-year in the most recent quarter, ahead of the Street’s modeled decline.
- Catalyst watch: Dupixent expansion into chronic spontaneous urticaria, the Telix radiopharmaceutical collaboration, and Q1 2026 earnings (late April).
What Is Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals is a Tarrytown, New York-based biotech that develops and commercialises monoclonal antibodies and protein-based therapeutics. The company runs a fully integrated discovery engine — including its proprietary VelociSuite genetic-engineering platform — and partners with Sanofi on flagship asset Dupixent. The portfolio anchors on three pillars: Eylea / Eylea HD in retinal disease, Dupixent in atopic dermatitis and asthma, and Libtayo in oncology, with an emerging pipeline in radiopharmaceuticals via Telix.
REGN is one of the largest pure-play biotechs in the S&P 500, with a market cap of roughly $80 billion. The stock has historically traded at a premium because of Dupixent’s near-monopoly position and Eylea’s blockbuster status. Both pillars are now under question — which is exactly why the stock is dropping.
Why Is REGN Stock Dropping in 2026?
The reason REGN stock is dropping in 2026 boils down to one franchise: Eylea. Amgen launched Pavblu (aflibercept-ayyh) in late 2024, and Samsung Bioepis cleared Opuviz in 2025. Both are FDA-approved biosimilars to the original Eylea 2mg formulation, and both have been winning formulary placement at major insurers and Medicare Part B plans through 2026. The result is a faster-than-modeled erosion in U.S. Eylea net sales — declines of roughly 25% year-over-year in recent quarters, with management acknowledging biosimilar pressure as the primary driver on the Q4 2025 call.
That matters because Eylea (in both formulations) historically contributed close to 40% of Regeneron’s net product sales. When 40% of revenue is in structural decline, the entire valuation framework resets. Adding to the pressure: the Inflation Reduction Act’s Medicare drug-price negotiation list could include aflibercept in a future cycle, and royalty disputes with Sanofi over Dupixent profit-share economics have created additional headline risk through Q1 2026.
The selling has been concentrated in long-only mutual fund holders rotating into mega-cap pharma names with cleaner near-term growth — Eli Lilly stock and Novo Nordisk on the GLP-1 trade, and AbbVie stock for the Skyrizi/Rinvoq franchise.
REGN Stock Price Recent Performance
REGN entered 2026 around $968 and has traded down to $748.87 by mid-April — a 22.6% YTD decline, well below the broader S&P 500 Healthcare sector. The stock is now roughly 38% below its 52-week high of $1,211.20, set in mid-2024 when Dupixent was still posting 30%+ growth and biosimilar timelines looked further out.
The major catalysts behind the move:
- February 2026: Q4 earnings showed accelerating Eylea base erosion. Stock dropped roughly 9% in a single session.
- March 2026: CMS preliminary 2027 negotiated-drug list speculation included aflibercept. Sector-wide pressure followed.
- April 2026: Stabilisation near $740-$760 as long-term value buyers stepped in following the Telix Pharmaceuticals collaboration announcement.
REGN Valuation Analysis: Is the Multiple Too Cheap?
At $748.87, REGN trades at roughly 17.3x forward earnings — a ~30% discount to the S&P 500 Healthcare average forward multiple of 25x. This is the cheapest REGN has been on a forward P/E basis since 2018.
| Multiple | REGN | Healthcare Sector Avg | Implied Discount |
|---|---|---|---|
| Forward P/E | 17.3x | 25.0x | -31% |
| EV / Revenue (TTM) | 5.4x | 4.8x | +13% |
| EV / EBITDA | 10.8x | 15.0x | -28% |
| PEG (3-yr forward) | 1.6x | 1.9x | -16% |
The market is pricing in continued Eylea base-version decay and only modest Eylea HD substitution. If Eylea HD ramp meets management’s guidance for 2027 — combined with Dupixent’s continued double-digit growth and Libtayo’s expanded indications — the current multiple looks too punitive. If biosimilar erosion accelerates further or Dupixent peaks earlier than expected, the multiple stays compressed.
Bullish and Bearish Analyst Opinions on REGN
| Reasons for the Decline (Bear) | Reasons the Drop Is Overdone (Bull) |
|---|---|
| Eylea biosimilars (Pavblu, Opuviz) eroding the U.S. base ~25% YoY | Eylea HD extended dosing label adds ~$3-4B peak revenue potential |
| ~40% of historical revenue concentrated in the Eylea franchise | Dupixent (50/50 with Sanofi) still growing >15%, EU CSU approval added in 2026 |
| CMS / IRA Medicare negotiation overhang on aflibercept | ~$8B net cash, allowing buybacks and bolt-on M&A at depressed multiples |
| Sanofi profit-share dispute creating headline risk | Telix Pharmaceuticals radiopharmaceutical collaboration adds new modality optionality |
| Long-only rotation out of biotech into mega-cap pharma | Forward P/E 17.3x is the cheapest since 2018 — historically a buy zone |
REGN Analyst Price Targets and Consensus Rating
Wall Street consensus on REGN sits at Moderate Buy with an average 12-month price target of $805 — implying ~7.5% upside from current levels. The dispersion is wide, reflecting genuine debate on biosimilar erosion pace.
- Bernstein — Outperform, $921 price target. Argues Eylea HD substitution rate is being underestimated and Dupixent growth runway extends through 2030.
- Morgan Stanley — Equal-Weight, $796 price target. Sees the valuation as fair but wants confirmation that Eylea HD scripts are accelerating before upgrading.
- JPMorgan — Overweight, $850 price target. Highlights $8B net cash and the potential for accretive M&A.
- Goldman Sachs — Neutral, $740 price target. Cautious on the Eylea cliff timing.
- UBS — Buy, $880 price target. Calls the current valuation “the most compelling entry in five years.”
The market here is pricing a base case where Eylea HD only partially offsets biosimilar erosion. If Q1 2026 earnings show Eylea HD scripts accelerating — and management has guided for a meaningful inflection — the bull-side targets ($880-$921) become the relevant anchor. Until that print, Hold remains the appropriate stance.
How to Trade REGN via MEXC
You can trade REGN as a tokenized stock 24/7 on MEXC — no U.S. brokerage account required, settled in USDT. The REGN USDT exchange pair tracks Regeneron’s price action and lets you go long or short outside traditional NYSE hours, including during pre-market biotech catalyst news (Q1 earnings, FDA decisions, CMS announcements).
Tokenized REGN gives crypto-native traders direct exposure without needing to open a separate equities account. The instrument is particularly useful for trading binary biotech catalysts where the move happens after the U.S. close.
REGN Stock FAQ
Why is REGN stock dropping in 2026?
REGN stock is dropping primarily because Eylea biosimilars from Amgen (Pavblu) and Samsung Bioepis (Opuviz) are eroding U.S. Eylea net sales faster than the Street modelled — roughly 25% year-over-year in recent quarters. Eylea historically contributed ~40% of Regeneron’s revenue, so the decline resets the entire valuation framework.
Is REGN a good stock to buy at $748?
REGN at $748 is a credible Hold with upside skewed positive. Forward P/E of 17.3x is the cheapest since 2018, the average analyst target of $805 implies modest upside, and bull-side targets reach $880-$921 if Eylea HD ramps as guided. The risk is further biosimilar erosion before HD scripts inflect — most likely a Q1 2026 earnings event.
Is the REGN drop overdone?
Bull-side analysts at Bernstein and UBS argue yes — the multiple has compressed to crisis-era levels while Dupixent growth, $8B net cash, and the Eylea HD label extension create asymmetric upside. Bears at Goldman counter that the Eylea cliff hasn’t fully played out. The honest answer: the drop is overdone IF Eylea HD substitutes at the pace management has guided. That thesis becomes testable on the Q1 2026 print.
What is the highest analyst price target on REGN?
The highest published target is Bernstein’s $921, premised on Eylea HD adoption exceeding 60% of the legacy Eylea base by end-2027 and Dupixent growth sustaining above 15%.
Should I buy the dip on REGN?
For long-term investors comfortable with a 2-3 year horizon, accumulating REGN in the $740-$770 range is defensible — valuation is at a multi-year low and the pipeline (Eylea HD, Dupixent expansions, Telix radiopharma collaboration) supports a recovery thesis. For shorter-term traders, waiting for the Q1 2026 earnings print to confirm Eylea HD ramp is the more disciplined approach.
Disclaimer
This article is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Past performance does not guarantee future results. Investors should conduct thorough due diligence and consult qualified financial advisors before making investment decisions.
MEXC is a global cryptocurrency exchange committed to “MEXCmize Your Opportunities.” Serving over 40 million users across 170+ countries, MEXC offers access to more than 3,000 digital assets across spot and derivatives markets. Known for its high liquidity and broad selection of trending tokens, the platform is designed to support both new traders and experienced investors. MEXC also continues to enhance trading efficiency through innovations such as zero trading fees, while prioritizing a secure, user-friendly, and accessible trading experience. Select MEXC as Your 0-fee Gateway To Infinite Opportunities.